Anna J. van Gestel

ORCID: 0000-0001-9122-0110
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Gastric Cancer Management and Outcomes
  • Colorectal Cancer Surgical Treatments
  • Colorectal Cancer Treatments and Studies
  • Lung Cancer Treatments and Mutations
  • Colorectal and Anal Carcinomas
  • Privacy-Preserving Technologies in Data
  • Data Quality and Management
  • Head and Neck Surgical Oncology
  • Cancer Risks and Factors
  • Sarcoma Diagnosis and Treatment
  • Head and Neck Cancer Studies
  • Cervical Cancer and HPV Research
  • Melanoma and MAPK Pathways
  • Radiomics and Machine Learning in Medical Imaging
  • Endometrial and Cervical Cancer Treatments
  • Mobile Crowdsensing and Crowdsourcing

Netherlands Comprehensive Cancer Organisation
2022-2025

In the last few years, federated learning (FL) has emerged as a novel alternative for analyzing data spread across different parties without needing to centralize them. order increase adoption of FL, there is need develop more algorithms that can be deployed under this privacy-preserving paradigm. paper, we present our generalized linear model (GLM) horizontally partitioned data. It allows generating models families (linear, Poisson, logistic) disclosing privacy-sensitive individual records....

10.3390/a15070243 article EN cc-by Algorithms 2022-07-13

The head and neck cancers (HNCs) incidence differs between Europe East Asia. Our objective was to determine whether survival of HNC also European Asian countries.We used population-based cancer registry data calculate 5-year relative (RS) for the oral cavity, hypopharynx, larynx, nasal major salivary gland in Europe, Taiwan, Japan. We modeled RS with a generalized linear model adjusting time since diagnosis, sex, age, subsite, histological grouping. Analyses were performed using federated...

10.3389/fonc.2023.1219111 article EN cc-by Frontiers in Oncology 2023-09-13

3589 Background: Approximately 10-15% of patients with metastatic colorectal cancer (mCRC) have BRAF V600E mutated tumors. Encorafenib plus cetuximab (EC) combination treatment was approved following the results randomized phase III BEACON trial and is currently recommended for all pretreated -mutant mCRC. Selection in controlled trials based on restrictive eligibility criteria often not representative patient population daily clinical practice. Complementary real-world effectiveness studies...

10.1200/jco.2023.41.16_suppl.3589 article EN Journal of Clinical Oncology 2023-06-01

3612 Background: The number of lymph nodes (LN) examined is a key factor in determining the stage colorectal cancer. Over past 20 years, examination fewer than 12 LN has been regarded as poor prognosis. However, surgical procedures and pathologic improvements have increased examined. This raised question reassessing best cutoff point for staging colon cancer patients undergoing curative surgery. Methods: We reviewed total 3,126 eligible with II-III collected from Yonsei Cancer Center...

10.1200/jco.2023.41.16_suppl.3612 article EN Journal of Clinical Oncology 2023-06-01
Coming Soon ...